Recombinant Human Granulocyte-Colony Stimulating Factor (rh G-CSF) in Standard Chemotherapy of Hodgkin?s Disease

Ann Med Res. 1998; 5(1): 24-29

Fahir Özkalemkaş¹, MD, Rıdvan Ali¹, MD, Yusuf Karaaslan¹, MD, Vildan Özkocaman¹, MD, Ahmet Tunalı¹, MD

Abstract
The aim of this study was to evaluate the effectiveness of recombinant granulocyte colony stimulating factor (rhG-CSF) administered following cytotoxic chemotherapy in Hodgkin's disease. Total number of 26 courses of rhG-CSF were applied in 19 patients with Hodgkin's disease aged 15 to 61 (median 44) years. They received MOPP (Nitrogen Mustard, Vincritine, Procarbazine, Prednisone) chemotherapy every 28 days. rhG-CSF was given at a dose of 5^/kg daily and subcutaneously from day 2nd to 6th day 8th to 20h unless the neutrophil count exceeded 10.000/mm3, in which case rhG-CSF discontinued. The outcome was compared with 24 prognostically similar control patients treated with the same chemotherapy without rhG-CSF. Recovery of granulocyte counts above 1000/mm was significantly faster in the rhG-CSF treated group (3±0.72 days vs 7±0.81 days; p